Genesis of an emergency public drug information website by the French Society of Pharmacology and Therapeutics during the COVID-19 pandemic.
Betacoronavirus
/ drug effects
COVID-19
Consumer Health Information
/ methods
Coronavirus Infections
/ drug therapy
Drug Information Services
/ organization & administration
France
Humans
Pandemics
Pneumonia, Viral
/ drug therapy
Public Health
/ methods
SARS-CoV-2
Social Networking
Societies, Pharmaceutical
COVID-19
pharmacology
public drug information
public health
Journal
Fundamental & clinical pharmacology
ISSN: 1472-8206
Titre abrégé: Fundam Clin Pharmacol
Pays: England
ID NLM: 8710411
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
received:
01
05
2020
revised:
05
05
2020
accepted:
06
05
2020
pubmed:
13
5
2020
medline:
17
6
2020
entrez:
13
5
2020
Statut:
ppublish
Résumé
On March 16, 2020, the French Society of Pharmacology and Therapeutics put online a national Question and Answer (Q&A) website, https://sfpt-fr.org/covid19 on the proper use of drugs during the COVID-19 pandemic. The working group 'Drugs and COVID-19' was composed of a scientific council, an editorial team, and experts in the field. The first questions were posted online during the first evening of home-confinement in France, March 17, 2020. Six weeks later, 140 Q&As have been posted. Questions on the controversial use of hydroxychloroquine and to a lesser extent concerning azithromycin have been the most consulted Q&As. Q&As have been consulted 226 014 times in 41 days. This large visibility was obtained through an early communication on Twitter, Facebook, traditional print, and web media. In addition, an early communication through the French Ministry of Health and the French National Agency for Medicines and Health Products Safety ANSM had a large impact in terms of daily number of views. There is a pressing need to sustain a public drug information service combining the expertise of scholarly pharmacology societies, pharmacovigilance network, and the Ministry of Health to quickly provide understandable, clear, expert answers to the general population's concerns regarding COVID-19 and drug use and to counter fake news.
Identifiants
pubmed: 32394481
doi: 10.1111/fcp.12564
pmc: PMC7273039
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
389-396Subventions
Organisme : Agence Nationale de Sécurité du Médicament et des Produits de Santé
Informations de copyright
© 2020 Société Française de Pharmacologie et de Thérapeutique.
Références
J Travel Med. 2020 May 18;27(3):
pubmed: 32307545
BMJ. 2020 Apr 24;369:m1587
pubmed: 32332066
JMIR Public Health Surveill. 2020 May 5;6(2):e19374
pubmed: 32338613
Lancet. 2020 Feb 29;395(10225):685-686
pubmed: 32059801
Therapie. 2014 Jul-Aug;69(4):355-66
pubmed: 25099666
JAMA. 2018 Dec 18;320(23):2417-2418
pubmed: 30428002
JAMA Intern Med. 2020 Aug 1;180(8):1116-1118
pubmed: 32347895
Health Policy. 2017 Mar;121(3):257-264
pubmed: 28073580
J Med Internet Res. 2020 Apr 21;22(4):e19016
pubmed: 32287039
Int J Antimicrob Agents. 2020 Jul;56(1):105949
pubmed: 32205204